Full Press Release Details
| June 13, 2024
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Read More
VANI Positive Sentiment
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Key Takeaway: Vivani Medical has announced that the FDA has cleared its Investigational New Drug Application for NPM-119, a miniature long-term subdermal GLP-1 drug implant. This decision also lifts the clinical hold previously placed on the product, allowing the company to proceed with its clinical trials. The development is seen as a significant step forward in the company's drug delivery technology.
Price reaction · baseline $1.63 (2024-06-12 close) · hit pre-market · clean, no other VANI news in the window
day 0 close
-0.6%
day 1
-1.8%
day 3 · peak
-18.4%
Market Sentiment Analysis
POSITIVE FACTORS
- FDA clearance of Investigational New Drug Application for NPM-119.
- Clinical hold lifted, allowing progress in trials.
- Potential for innovative long-term GLP-1 drug delivery.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~10 mo
Medium dilution risk
Lead asset
Semaglutide
Phase 1 · Obesity & Overweight
Frequently Asked Questions
What is NPM-119?
NPM-119 is a miniature long-term subdermal GLP-1 drug implant developed by Vivani Medical.
What did the FDA announce regarding NPM-119?
The FDA cleared the Investigational New Drug Application for NPM-119 and lifted the clinical hold.
What does the FDA clearance mean for Vivani Medical?
The clearance allows Vivani Medical to proceed with clinical trials for NPM-119.
What type of drug is NPM-119?
NPM-119 is a GLP-1 drug implant designed for long-term delivery.